Format

Send to

Choose Destination
Expert Opin Ther Targets. 2008 Oct;12(10):1265-74. doi: 10.1517/14728222.12.10.1265 .

Targeting glycogen synthase kinase-3 (GSK-3) in the treatment of Type 2 diabetes.

Author information

1
Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario M5G 1X5, Canada.

Abstract

BACKGROUND:

In spite of its rather specific name, glycogen synthase kinase-3 (GSK-3) is an eclectic cellular regulator that modulates an array of processes from nuclear transcription, to neurological functions and metabolism. The enzyme is also a focal point for diverse signaling pathways that act to suppress its activity.

OBJECTIVES:

To review recent evidence supporting the important role GSK-3 plays in glucose homeostasis and discuss the therapeutic potential of inhibiting this enzyme in the treatment of diabetes and insulin resistance.

RESULTS/CONCLUSION:

Despite its pleiotropic nature, GSK-3 has significant promise as a target for diabetes due to functional partitioning of the enzyme, tissue-selectivity and acute dosage-dependency of effects of inhibition, suggesting useful therapeutic windows.

PMID:
18781825
PMCID:
PMC4485462
DOI:
10.1517/14728222.12.10.1265
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center